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Backgrounds: People with AIDS have an increased risk of developing 
various bacterial infection such as Mycobacterium tuberculosis. Children 
with AIDS have a better oppurtunity to TB relapse than children who are 
not with AIDS. The appropriate management of HIV-associated TB in 
children remains extremely challenging due to diagnostic difficulties, 
multidrug resistant, the overlapping side effect profiles of anti-TB and 
ARV,  the complexity of drug-drug interactions and IRIS after initiation of 
ARV. 
Objective: To analyze the profile of antituberculosis drugs used in 
tuberculosis infection with AIDS and to identify drug related problems 
(DRPs) of antituberculosis drug.  
Method: It was a retrospective study during period January 2013 to 
December 2015 in children  with AIDS ages 0 to 14 years receiving anti 
tuberculosis.  
Result and Discussion: Dose antituberculosis in intensive phase is FDC (R 
75 mg, H 50 mg, and Z 150 mg) (1 x 1, 2, 3 and 4 tabs) po, FDC (R 37 mg, 
H 37 mg, Z 111 mg) 1x¾ tab and FDC (R 90 mg, 60 mg H, Z 180 mg) 
1x1,5 tab. Ethambutol dose is (1 x 110, 130, 200 and 400 mg) po. HES dose 
is H 1x145 mg, 1x360 mg E and S 1x300 mg IM. Doses intermediate phase 
is FDC (R 75 mg and H 50 mg. The problems that occur related to drugs is 
a side effect of H which causes numbness or tingling of hands and feet, 
RHZ cause hepatotoxicity and drug interactions of potential anti-
tuberculosis (R) and the anti-retroviral (evavirenz, nevirapine, zidovudine). 
Conclusion : Antituberculosis drugs use in children with  AIDS were 
isoniazid, rifampicin, pyrazinamide, and ethambutol in combination. Route 
of administration of anti tuberculosis RHZE by oral and S by intramuscular. 
The dose in children were adjusted to the weight of patient.  
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